Monday, August 24, 2015
Nonprice Competition in 'Substitute' Drugs: The FTC's Blind Spot
Gregory Dolin, University of Baltimore - School of Law describes Nonprice Competition in 'Substitute' Drugs: The FTC's Blind Spot. ABSTRACT: As the recent case of United States v. Lundbeck illustrates, the Federal Trade Commission’s lack of knowledge in medical and...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment